We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+13.82%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.39B
AUM Growth
+$50.3M
(+3.8%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
1.68%
Top 10 Holdings %
Top 10 Hldgs %
66.53%
Holding
65
New
17
Increased
7
Reduced
4
Closed
19
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
+$122M |
| 2 |
Nurix Therapeutics
NRIX
|
+$30M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$14.6M |
| 4 |
BCEL
Atreca, Inc. Class A Common Stock
BCEL
|
+$14M |
| 5 |
KLRS
Kalaris Therapeutics
KLRS
|
+$13.3M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$69.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$40.6M |
| 3 |
Fate Therapeutics
FATE
|
+$21.3M |
| 4 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$20.5M |
| 5 |
Denali Therapeutics
DNLI
|
+$17.7M |
Sector Composition
| 1 | Healthcare | 97.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xencor
XNCR
$1.11B
| $176M | 12.73% |
4,547,072
| – | – |
|
2
Kura Oncology
KURA
$1.01B
| $141M | 10.19% |
4,608,529
| – | – |
|
|
3
Relay Therapeutics
RLAY
$4.25B
| $136M | 9.84% |
+3,200,649
| New | +$122M |
|
4
Prothena Corp
PRTA
$441M
| $94.2M | 6.79% |
9,426,640
| – | – |
|
|
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $77.6M | 5.6% |
2,839,884
+1,911
| +0.1% | +$50.1K |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $77.1M | 5.56% |
464,298
+106,449
| +30% | +$14.6M |
|
7
Oric Pharmaceuticals
ORIC
$1.15B
| $66.1M | 4.77% |
2,642,218
| – | – |
|
|
RNAM
8
DELISTED
Avidity Biosciences
RNAM
| $59.2M | 4.27% |
2,103,950
| – | – |
|
9
AnaptysBio
ANAB
$1.65B
| $47.5M | 3.43% |
3,223,324
+148,310
| +5% | +$2.68M |
|
10
Neurogene
NGNE
$787M
| $46.4M | 3.34% |
193,147
+16,313
| +9% | +$3.95M |
|
|
AKUS
11
DELISTED
Akouos Inc
AKUS
| $45.2M | 3.26% |
1,975,984
| – | – |
|
12
Assembly Biosciences
ASMB
$530M
| $41.9M | 3.02% |
212,365
-50,451
| -19% | -$12.7M |
|
|
13
Nurix Therapeutics
NRIX
$2.48B
| $41.6M | 3% |
+1,192,156
| New | +$30M |
|
|
AMTI
14
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $36.6M | 2.64% |
1,150,000
| – | – |
|
|
BCEL
15
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $33.9M | 2.45% |
2,426,685
+937,500
| +63% | +$14M |
|
16
Geron
GERN
$911M
| $33.5M | 2.41% |
19,230,769
| – | – |
|
17
Sutro Biopharma
STRO
$431M
| $31.3M | 2.26% |
311,362
+128,513
| +70% | +$12.1M |
|
18
Arcus Biosciences
RCUS
$3.52B
| $31M | 2.24% |
1,810,000
| – | – |
|
|
SURF
19
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $23M | 1.66% |
3,333,177
-1,700,684
| -34% | -$10.3M |
|
20
Cyclerion Therapeutics
CYCN
$16.1M
| $16.7M | 1.2% |
137,114
| – | – |
|
|
KLRS
21
Kalaris Therapeutics
KLRS
$115M
| $12.3M | 0.89% |
+19,435
| New | +$13.3M |
|
|
CBIO
22
Crescent Biopharma
CBIO
$432M
| $11.4M | 0.83% |
37,252
+18,362
| +97% | +$7.02M |
|
23
Tango Therapeutics
TNGX
$4.93B
| $8.29M | 0.6% |
+800,000
| New | +$8.17M |
|
|
VINC
24
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $7.82M | 0.56% |
+31,525
| New | +$6.41M |
|
|
ALPN
25
DELISTED
Alpine Immune Sciences Inc
ALPN
| $6.52M | 0.47% |
+741,290
| New | +$6.78M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM